尿激酶溶栓治疗对急性脑梗死出血患者血清基质金属蛋白酶―9水平影响.docVIP

尿激酶溶栓治疗对急性脑梗死出血患者血清基质金属蛋白酶―9水平影响 　　[摘要] 目的 探讨尿激酶溶栓治疗对急性脑梗死出血患者血清基质金属蛋白酶-9（MMP-9）水平的变化及其临床疗效。 方法 选择2012年10月～2015年10月在我院诊治的急性脑梗死出血患者80例，根据随机数字表法分为治疗组与对照组各40例。常规基础治疗基础上，对照组应用重组组织型纤溶酶原激活剂溶栓治疗，治疗组应用尿激酶溶栓治疗，观察两组患者神经功能缺损、临床疗效、并发症及血清MMP-9水平的变化，治疗观察时间为7 d。结果 治疗后治疗组与对照组NIHSS评分分别为（6.35±1.33）分和（9.18±1.83）分，明显低于治疗前的（14.25±1.55）分和（14.28±1.86）分（P0.05），同时组间比较差异有统计学意义（P0.05）。经过治疗，对照组和治疗组的有效率分别为82.5%、95.0%。治疗组治疗期间的再出血、颅内感染、迟发脑积水等并发症发生情况明显少于对照组（P0.05）。治疗后治疗组与对照组血清MMP-9含量分别为（82.33±12.83）ng/mL和（182.33±11.44）ng/mL，明显低于治疗前的（534.25±16.12）ng/mL和（531.28±21.23）ng/mL（P0.05），同时组间比较差异有统计学意义（P0.05）。结论 尿激酶溶栓治疗能缓解急性脑梗死出血患者神经功能障碍，降低并发症的发生，从而提高治疗疗效，其作用的发挥可能与有效促进血清MMP-9含量降低有关。 　　[关键词] 尿激酶；溶栓治疗；急性脑梗死；脑出血；基质金属蛋白酶-9 　　[中图分类号] R743.3 [文献标识码] A [文章编号] 1673-9701（2016）17-0001-03 　　Effect of intravenous thrombolytic therapy with urokinase on serum matrix metalloproteinase -9 levels in patients with acute cerebral infarction and hemorrhage 　　SHA Dan LIN Wentao 　　Department of Clinical Laboratory， the First Peoples Hospital of Xiantao City in Hubei Province， Xiantao 433000， China 　　[Abstract] Objective To investigate the changes of serum matrix metalloproteinase -9 （MMP-9） levels and the clinical effects analysis of urokinase thrombolytic therapy in patients with acute cerebral infarction and hemorrhage. Methods 80 patients with acute cerebral infarction and hemorrhage in our hospital from October 2012 to October 2015 were divided into the treatment group and the control group according to the random number table method， 40 cases in each group. On the basis of the conventional treatment， the control group was treated with the recombinant tissue plasminogen activator thrombolysis， and the treatment group was given the urokinase thrombolytic therapy. The neurological function，clinical efficacy，complications and changes of serum MMP-9 levels were observed. Treatment lasted for 7d. Results After treatment， the NIHSS scores in the treatment group and the control group were（6.35±1.33） points and （9.18±1.83） p